43.06
price down icon2.89%   -1.28
 
loading
Grail Inc stock is traded at $43.06, with a volume of 1.57M. It is down -2.89% in the last 24 hours and down -55.84% over the past month. GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$44.34
Open:
$43.44
24h Volume:
1.57M
Relative Volume:
1.28
Market Cap:
$1.74B
Revenue:
$147.17M
Net Income/Loss:
$-408.35M
P/E Ratio:
-3.852
EPS:
-11.1787
Net Cash Flow:
$-299.01M
1W Performance:
-14.27%
1M Performance:
-55.84%
6M Performance:
+13.20%
1Y Performance:
+59.96%
1-Day Range:
Value
$41.53
$44.95
1-Week Range:
Value
$41.53
$51.15
52-Week Range:
Value
$20.44
$118.84

Grail Inc Stock (GRAL) Company Profile

Name
Name
Grail Inc
Name
Phone
(833) 694-2553
Name
Address
1525 O'BRIEN DRIVE, MENLO PARK
Name
Employee
1,000
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
GRAL's Discussions on Twitter

Compare GRAL vs TMO, DHR, IDXX, A, WAT

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
GRAL
Grail Inc
43.06 1.74B 147.17M -408.35M -299.01M -11.18
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
464.37 172.51B 44.56B 6.72B 6.29B 17.74
Diagnostics & Research icon
DHR
Danaher Corp
187.32 132.46B 24.57B 3.60B 5.26B 5.051
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
573.82 45.69B 4.30B 1.06B 1.04B 13.08
Diagnostics & Research icon
A
Agilent Technologies Inc
111.51 31.51B 7.07B 1.29B 993.00M 4.5355
Diagnostics & Research icon
WAT
Waters Corp
286.57 28.11B 3.17B 642.63M 516.49M 10.77

Grail Inc Stock (GRAL) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-19-26 Initiated TD Cowen Hold
Feb-17-26 Initiated Robert W. Baird Outperform
Dec-02-25 Resumed Morgan Stanley Equal-Weight
Nov-12-25 Upgrade Guggenheim Neutral → Buy
Apr-21-25 Initiated Canaccord Genuity Buy
Nov-27-24 Initiated Morgan Stanley Equal-Weight
Nov-15-24 Initiated Wolfe Research Peer Perform
Oct-17-24 Initiated Guggenheim Neutral
View All

Grail Inc Stock (GRAL) Latest News

pulisher
08:06 AM

Canaccord Genuity Reaffirms Their Buy Rating on GRAIL Inc (GRAL) - The Globe and Mail

08:06 AM
pulisher
Mar 13, 2026

GRAIL Inc (GRAL) Shares Down 4.59% on Mar 13 - GuruFocus

Mar 13, 2026
pulisher
Mar 13, 2026

Assessing GRAIL (GRAL) Valuation After Recent Share Price Volatility and Narrative Fair Value Gap - simplywall.st

Mar 13, 2026
pulisher
Mar 13, 2026

Grail Inc. Announces CEO Transition - Contract Pharma

Mar 13, 2026
pulisher
Mar 13, 2026

Grail CEO to retire after failed cancer detection trialSan Francisco Business Times - The Business Journals

Mar 13, 2026
pulisher
Mar 13, 2026

GRAIL names Josh Ofman as CEO, Bob Ragusa to retire June 1 - Investing.com Canada

Mar 13, 2026
pulisher
Mar 12, 2026

GRAIL, Inc. Hits Day High with 12.18% Surge Amid Market Challenges - Markets Mojo

Mar 12, 2026
pulisher
Mar 12, 2026

(GRAL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Mar 12, 2026
pulisher
Mar 12, 2026

Freidin, Grail CFO, sells $154k in GRAL stock - Investing.com Nigeria

Mar 12, 2026
pulisher
Mar 12, 2026

Grail CEO Bob Ragusa retiring, Josh Ofman appointed successor - TipRanks

Mar 12, 2026
pulisher
Mar 12, 2026

GRAIL, Inc. 2025 Annual Report: Multi-Cancer Early Detection with Galleri, Company Strategy, and Key Business Risks - Minichart

Mar 12, 2026
pulisher
Mar 12, 2026

GRAIL, Inc. Announces Chief Executive Officer Changes, Effective June 1, 2026 - marketscreener.com

Mar 12, 2026
pulisher
Mar 12, 2026

Cancer detection company GRAIL elevates Josh Ofman to lead multi-cancer efforts - Stock Titan

Mar 12, 2026
pulisher
Mar 12, 2026

Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire

Mar 12, 2026
pulisher
Mar 11, 2026

Here's Why Grail Shares Crashed in February and Why it Could Be a Buying Opportunity - AOL.com

Mar 11, 2026
pulisher
Mar 10, 2026

Grail Inc’s Earnings Call Balances Momentum and Risk - TipRanks

Mar 10, 2026
pulisher
Mar 10, 2026

A Persistent Patient’s Story - RealClearHealth

Mar 10, 2026
pulisher
Mar 09, 2026

Aaron Freidin Sells 2,492 Shares of GRAIL (NASDAQ:GRAL) Stock - MarketBeat

Mar 09, 2026
pulisher
Mar 09, 2026

Joshua Ofman Sells 2,937 Shares of GRAIL (NASDAQ:GRAL) Stock - MarketBeat

Mar 09, 2026
pulisher
Mar 09, 2026

Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 7,461 Shares of Stock - MarketBeat

Mar 09, 2026
pulisher
Mar 09, 2026

Freidin, Grail CFO, sells $154k in GRAL stock By Investing.com - Investing.com Australia

Mar 09, 2026
pulisher
Mar 09, 2026

Ofman Joshua J. (GRAIL) sells $177k in shares - Investing.com South Africa

Mar 09, 2026
pulisher
Mar 09, 2026

Grail CEO Ragusa sells $409k in shares - Investing.com India

Mar 09, 2026
pulisher
Mar 09, 2026

GRAIL (GRAL) president sells 3,627 shares in automatic tax sell-to-cover - Stock Titan

Mar 09, 2026
pulisher
Mar 09, 2026

GRAL Stock Price, Quote & Chart | GRAIL INC (NASDAQ:GRAL) - ChartMill

Mar 09, 2026
pulisher
Mar 07, 2026

Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia - samsung.com

Mar 07, 2026
pulisher
Mar 07, 2026

Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - The Cancer Letter

Mar 07, 2026
pulisher
Mar 07, 2026

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.” Mainstream epidemiologists beg to differ - The Cancer Letter

Mar 07, 2026
pulisher
Mar 06, 2026

GRAIL, Inc. $GRAL Shares Purchased by JPMorgan Chase & Co. - MarketBeat

Mar 06, 2026
pulisher
Mar 06, 2026

How Investors Are Reacting To GRAIL (GRAL) Mixed NHS-Galleri Trial Results And Ongoing Net Losses - Sahm

Mar 06, 2026
pulisher
Mar 05, 2026

POM Health Announces Agreement with GRAIL to Offer Its Galleri® MCED Test - PR.com

Mar 05, 2026
pulisher
Mar 05, 2026

Here's Why Grail Stock Bounced Back 16% Today - AOL.com

Mar 05, 2026
pulisher
Mar 05, 2026

Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire

Mar 05, 2026
pulisher
Mar 05, 2026

Vanguard Group Inc. Trims Stock Position in GRAIL, Inc. $GRAL - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

Crcm LP Has $108.96 Million Holdings in GRAIL, Inc. $GRAL - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

GRAIL, Inc. Hits Day Low of $41.50 Amid Price Pressure - Markets Mojo

Mar 05, 2026
pulisher
Mar 04, 2026

GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES - Seeking Alpha

Mar 04, 2026
pulisher
Mar 04, 2026

Grail Insider Sold Shares Worth $1,881,417, According to a Recent SEC Filing - marketscreener.com

Mar 04, 2026
pulisher
Mar 03, 2026

GRAIL (NASDAQ:GRAL) CFO Aaron Freidin Sells 9,573 Shares - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 37,504 Shares of Stock - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

GRAL | GRAIL, Inc. Common Stock FinancialsIncome Statement - Quiver Quantitative

Mar 03, 2026
pulisher
Mar 03, 2026

GRAIL (GRAL) president gets RSU grant, sells shares for taxes - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

GRAIL (GRAL) CFO awarded 60,118 RSUs, sells shares to cover taxes - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

GRAIL (GRAL) CEO sells 37,504 shares in automatic tax sell-to-cover - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

GRAIL, Inc. (GRAL) Stock Analysis: Investor Outlook On A 67.21% Potential Upside - DirectorsTalk Interviews

Mar 03, 2026
pulisher
Mar 03, 2026

GRAL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

GRAIL, Inc. Hits Day Low of $52.56 Amid Price Pressure - Markets Mojo

Mar 03, 2026
pulisher
Mar 03, 2026

GRAL: NHS-Galleri trial showed strong stage 4 cancer reduction and broad commercial momentum - TradingView

Mar 03, 2026
pulisher
Mar 02, 2026

GRAIL (GRAL) Valuation Check As NHS Galleri Trial Data And Earnings Reset Growth Expectations - simplywall.st

Mar 02, 2026
pulisher
Mar 02, 2026

GRAL: Affiliate to sell 36,923 vested RSU shares (Form 144) - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

GRAL (NASDAQ) insider sale: Robert Ragusa sells 40,000 shares; 74,873 RSUs vested - Stock Titan

Mar 02, 2026

Grail Inc Stock (GRAL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
diagnostics_research LH
$263.80
price up icon 0.34%
diagnostics_research DGX
$199.70
price down icon 0.59%
diagnostics_research MTD
$1,173.74
price up icon 0.49%
$187.85
price down icon 1.29%
diagnostics_research IQV
$164.72
price up icon 1.10%
diagnostics_research WAT
$286.57
price up icon 1.15%
Cap:     |  Volume (24h):